Change: + 0.13
Day High: 7.75
Day Low: 7.40
12:36 PM ET | Dec 6, 2016
Delayed 20 min., by eSignal.
Prabhavathi Fernandes Ph.D.
President and Chief Executive Officer
Mark W. Hahn
Executive Vice President and Chief Financial Officer
Executive Vice President and Chief Commercial Officer
Mr. Moore is responsible for commercial development. He has spent over 15 years developing and managing pharmaceutical commercial programs, with the majority of those years spent with the Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson. Mr. Moore has held leadership roles in key sales and marketing functions, and was part of teams that developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings. He developed payer value platforms for several therapeutic areas including antibiotics, pain and women’s health, in which he successfully implemented pricing and reimbursement strategies with hospitals and managed care organizations. Following Johnson & Johnson, he was chief business officer and vice president of Worldwide Commercial Operations of Tranzyme, Inc., where he was responsible for building the commercial organization as well as in- and out-licensing clinical-stage assets and was chief business officer of Ocera Therapeutics where he was responsible for developing the commercial plans for an Orphan-designated advanced liver disease product for both the community and acute care markets. Mr. Moore received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.
Gary Horwith M.D.
Executive Vice President, Regulatory Affairs
Dr. Horwith oversees regulatory chemistry, manufacturing and controls (CMC) and clinical strategies. He has 30 years of experience in clinical research and regulatory affairs and has brought numerous NCEs, vaccines, and other biological products to the IND stage, conducted Phase 1-to-3 trials and filed several NDAs during his 11 years at Wyeth and 19 years at other biotechnology and biopharmaceutical companies. Dr. Horwith received his M.D. from Autonomous University of Guadalajara, completed a residency in Internal Medicine at the University of Connecticut, an Infectious Disease Fellowship at University of California Irvine, and was a principal investigator at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) before entering the pharmaceutical industry.
Carl T. Foster
Executive Vice President, Business Development
David Pereira Ph.D.
Senior Vice President of Chemistry
David Oldach M.D., FIDSA
Chief Medical Officer
David Oldach joined Cempra Pharmaceuticals in 2011. Between 2006 and 2011, Dr. Oldach directed clinical research at Gilead Sciences, Inc., where his drug development experience ranged from IND/first-in-human trial development and execution through NDA-supportive Phase 3 protocol development and execution. Dr. Oldach received his Medical Degree, Magna Cum Laude, from the University of Maryland School of Medicine and completed a residency in Internal Medicine at the Massachusetts General Hospital. He completed an Infectious Disease Fellowship at Johns Hopkins University School of Medicine, serving under John Bartlett. His academic clinical research included studies in community-acquired pneumonia and surgical infections, as well as HCV pathogenesis. At the time of his transition from academic medicine to industry, Dr. Oldach was a tenured Associate Professor of Medicine at the University of Maryland School of Medicine and served as the Infectious Diseases Section Chief in the Baltimore Veterans Administration Hospital.